D. Boral Capital Has Lowered Expectations for Quince Therapeutics (NASDAQ:QNCX) Stock Price

Quince Therapeutics (NASDAQ:QNCX) had its target price trimmed by D. Boral Capital from $12.00 to $4.00 in a research note published on Tuesday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

QNCX has been the subject of several other research reports. Oppenheimer initiated coverage on shares of Quince Therapeutics in a report on Monday. They set an “outperform” rating and a $10.00 price objective for the company. Brookline Capital Management began coverage on Quince Therapeutics in a research report on Wednesday, December 18th. They set a “buy” rating and a $9.00 price objective on the stock. Five equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $8.00.

Quince Therapeutics Stock Up 4.5 %

Shares of QNCX opened at $1.40 on Tuesday. The business’s 50 day moving average is $1.47 and its 200 day moving average is $1.44. The company has a current ratio of 9.53, a quick ratio of 9.53 and a debt-to-equity ratio of 0.33. Quince Therapeutics has a 12-month low of $0.51 and a 12-month high of $2.45. The company has a market capitalization of $61.60 million, a PE ratio of -1.13 and a beta of 0.71.

Quince Therapeutics (NASDAQ:QNCX) last released its quarterly earnings data on Monday, March 24th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.09). The firm had revenue of $0.17 million for the quarter. Research analysts expect that Quince Therapeutics will post -1.21 earnings per share for the current fiscal year.

Institutional Trading of Quince Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Two Sigma Investments LP purchased a new stake in Quince Therapeutics during the 4th quarter worth approximately $57,000. Shay Capital LLC lifted its position in shares of Quince Therapeutics by 60.8% during the 4th quarter. Shay Capital LLC now owns 276,799 shares of the company’s stock valued at $518,000 after buying an additional 104,616 shares in the last quarter. Northern Trust Corp raised its position in shares of Quince Therapeutics by 48.5% during the 4th quarter. Northern Trust Corp now owns 50,524 shares of the company’s stock worth $94,000 after purchasing an additional 16,501 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Quince Therapeutics by 10.9% in the fourth quarter. Geode Capital Management LLC now owns 375,932 shares of the company’s stock worth $703,000 after acquiring an additional 36,807 shares during the last quarter. Finally, Virtu Financial LLC purchased a new stake in shares of Quince Therapeutics during the fourth quarter worth $55,000. Hedge funds and other institutional investors own 30.75% of the company’s stock.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.